Soluble interleukin-2 receptor is a thyroid hormone-dependent early response marker in the treatment of thyrotoxicosis

Clinical and Diagnostic Laboratory Immunology

Volumn 4, Issue 5, 1997, Pages 583-586

  Smallridge, Robert C ^a   Tsokos, George C ^b   Burman, Kenneth D ^c,e   Porter, Lisa ^b   Cranston, Toni ^c   Sfikakis, Peter P ^d   Solomon, Barbara L ^c  

^a MAYO CLINIC   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; MARKER; THIAMAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MALE; MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THYROTOXICOSIS; UNITED STATES;

EID: 0030769825     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.4.5.583-586.1997     Document Type: Article

References (16)

1. Campen, D. H., D. A. Horwitz, F. P. Quismorio, Jr., G. R. Ehresmann, and W. J. Martin. 1988. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 31:1358-1364.
2. Chow, C. C., K. N. Lai, C. K. Leung, J. C. N. Chan, and C. S. Cockram. 1990. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy. Clin. Endocrinol. 33:317-321.
3. DeBellis, A., A. Bizzarro, A. Gattoni, C. Romano, S. DiMartino, A. A. Sinisi, S. Abbadessa, and A. Bellastella. 1995. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma. J. Clin. Endocrinol. Metab. 80:2118-2121.
4. Escobar-Morreale, H. F., J. Serrano-Gottarredona, L. M. Villar, R. Garcia-Robles, P. Gonzalez-Porqué, J. M. Sancho, and C. Varela. 1996. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and β-microglobulin in patients with Graves' disease. Thyroid 6:29-36.
5. Koukkou, E., P. Panayiotidis, V. Alevizou-Terzaki, and N. Thalassinos. 1991. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. J. Clin. Endocrinol. Metab. 73:771-776.
6. Lipnick, R. N., P. P. Sfikakis, G. L. Klipple, and G. C. Tsokos. 1993. Elevated soluble CDS antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis. Clin. Immunol. Immunopathol. 68:64-67.
7. Mariotti, S., P. Caturegli, G. Barbesino, G. F. Del Prete, L. Chiovato, and A. Pinchera. 1991. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogcnic hyperthyroidism. J. Endocrinol. Invest. 14:777-781.
8. Mariotti, S., P. Caturegli, G. Barbesino, M. Marino, G. F. Del Prete, L. Chiovato, M. Tonacchera, M. DeCarli, and A. Pinchera. 1992. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases. Clin. Endocrinol. 37:415-422.
9. Nakanishi, K., Y. Taniguchi, and Y. Ohta. 1991. Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease. Acta Endocrinol. (Copenhagen) 125:253-258.
10. Rubin, L. A., and D. L. Nelson. 1990. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann. Intern. Med. 113:619-627.
11. Sfikakis, P. P., J. Tesar, H. Baraf, R. Lipnick, G. Klipple, and G. C. Tsokos. 1993. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin. Immunol. Immunopathol. 68:88-92.
12. Sfikakis, P. P., D. Charalambopoulos, G. Vayiopoulos, R. Oglesby, P. Sfikakis, and G. C. Tsokos. 1994. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 12:5-9.
13. Sfikakis, P. P., and G. C. Tsokos. 1995. Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations. Clin. Exp. Rheumatol. 13:763-777.
14. Solomon, B. L., L. Wartofsky, and K. D. Burman. 1993. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin. Endocrinol. 38:39-13.
15. Solomon, B. L., T. Cranston, M. T. McDermott, A. Asp, and K. D. Burman. 1995. Treatment of Graves' disease with cholestyramine, abstr. OR11-2. In Program and abstracts of the 77th Annual Meeting of the Endocrine Society.
16. Wenisch, C., D. Myskiw, A. Gessl, and W. Graninger. 1995. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. J. Clin. Endocrinol. Metab. 80:2122-2126.